CRP and gout: Baseline factors associated with HRQoL improvements over 72 weeks of ULT included lower C-reactive protein level and lower comorbidity scores with similar changes observed by ULT assignment.<h4>Conclusion</h4>Treat-to-target ULT in gout is accompanied by HRQoL improvements evident by 24 weeks and sustained through 72 weeks.